Business Context and Reporting Period
Waystar Holding Corp. (Nasdaq: WAY) is a provider of mission-critical cloud software that simplifies healthcare payments for providers, patients, and payers. The company operates in a single reportable segment and serves over 30,000 clients, including 16 of the top 20 U.S. News Best Hospitals. This Form 10-K covers the fiscal year ended December 31, 2024. In June 2024, the company completed its Initial Public Offering (IPO), raising approximately $1.02 billion in net proceeds, which were primarily used to repay a significant portion of its outstanding debt.
Key Financial Metrics
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $943.5 million | $791.0 million | $704.9 million |
| Net Loss | $(19.1) million | $(51.3) million | $(51.5) million |
| Adjusted EBITDA | $383.5 million | $333.7 million | $295.5 million |
| Adjusted EBITDA Margin | 40.6% | 42.2% | 41.9% |
| Operating Cash Flow | $169.8 million | $51.5 million | $102.6 million |
| Total Debt Outstanding | $1.24 billion | $2.25 billion | N/A |
| Cash and Cash Equivalents | $182.1 million | $35.6 million | N/A |
Key Performance Metrics: The Net Revenue Retention Rate was 110.1% for 2024. The company had 1,203 clients generating over $100,000 in revenue during the year.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 19.3% year-over-year to $943.5 million. This growth was driven by a $57.0 million increase in subscription revenue and a $93.6 million increase in volume-based revenue. Approximately $34 million of this increase is attributed to heightened win rates and accelerated implementations following a cybersecurity incident at a major competitor in February 2024.
- Profitability Improvement: Net loss narrowed significantly from $51.3 million in 2023 to $19.1 million in 2024. This improvement was primarily due to a $59.6 million decrease in interest expense resulting from the substantial paydown of the First Lien Credit Facility and the full paydown of the Second Lien Credit Facility.
- Expense Increases: General and Administrative (G&A) expenses increased 77.6% to $111.8 million, largely due to a $26.3 million increase in stock-based compensation related to the IPO and $14.1 million in third-party fees associated with debt modifications and refinancing. Research and Development expenses increased 38.0% to $48.8 million due to higher personnel costs and stock-based compensation.
- Debt Reduction: Total outstanding debt decreased from $2.25 billion in 2023 to $1.24 billion in 2024. The company utilized IPO proceeds to repay approximately $1.02 billion of its First Lien Credit Facility and fully retired its Second Lien Credit Facility.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to continue driving growth by expanding relationships with existing clients (cross-selling and up-selling), growing the client base, and deepening channel partnerships. The company plans to invest heavily in platform innovation, including the use of generative AI, and selectively pursue strategic acquisitions. No specific numerical guidance for 2025 was provided in this filing.
Material Risks:
- Regulatory Environment: The company operates in a heavily regulated industry subject to complex federal and state laws, including HIPAA, the Anti-Kickback Statute, and the False Claims Act. Changes in healthcare reimbursement models or regulations could adversely affect client spending and transaction volumes.
- Cybersecurity: As a processor of sensitive healthcare data, the company faces risks from cyber-attacks, data breaches, and ransomware, which could result in significant liability, reputational damage, and operational disruption.
- Competition: The market is highly competitive with legacy vendors, point-solution providers, and EHR/PM system providers. Increased competition could lead to pricing pressure or loss of market share.
- Debt Obligations: Despite recent paydowns, the company maintains substantial indebtedness ($1.2 billion), which limits financial flexibility and exposes the company to interest rate fluctuations as a portion of the debt is variable-rate.
- Concentration of Ownership: Institutional Investors (EQT, CPPIB, and Bain) own approximately 66% of the outstanding common stock, allowing them to control or influence significant corporate actions.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the First Lien Credit Facility covenants, specifically the first lien leverage ratio, which is tested quarterly if revolver usage exceeds 35% of commitments.
- Stock-Based Compensation: Monitor the impact of the $54.4 million stock-based compensation expense recognized in 2024, particularly the $33.1 million related to the vesting of performance condition options triggered by the IPO.
- Competitor Impact Sustainability: Assess the sustainability of the $34 million revenue uplift attributed to the competitor's cybersecurity incident and whether this represents a one-time acceleration or a permanent market share shift.
- Interest Rate Exposure: Evaluate the company's exposure to rising interest rates on its variable-rate debt (SOFR + spread) and the effectiveness of its interest rate swap hedges.
- Regulatory Changes: Monitor developments in healthcare data privacy laws (e.g., state-level consumer health data laws) and potential impacts on the company's ability to process and monetize data.